INTERNATIONAL ADVISORY COMMITTEE ON CLINICAL TRIALS IN MULTIPLE SCLEROSIS
The International Advisory Committee on Clinical Trials in Multiple Sclerosis is jointly supported by the US National Multiple Sclerosis Society (NMSS) and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Click here for the Committee Charter. The Committee works to provide perspective and guidance in areas of interest to planning and implementation of clinical trials for new agents for the treatment of multiple sclerosis. The Committee works as a whole, in international meetings and consensus-building activities, or through subcommittees and task forces on specific topics. Historically, some of the Committee’s projects and publications of their outcomes have included:
- Outcomes assessment in MS clinical trials – The “Charleston Meeting” (1995)
- Defining the clinical course of MS (1996)
- Guidelines for MRI in monitoring MS treatment (1996)
- MRI for understanding and managing MS (1998)
- Development of the Multiple Sclerosis Functional Composite (1999)
- Diagnostic criteria for MS (2001 and 2005 and 2010) and differential diagnosis of MS (2008)
- The ethics of placebo-controlled clinical trials in MS (2001 and 2008)
- The impact of available therapies on clinical trial design (2005)
- MRI as a surrogate outcome for MS clinical trials (2008)
- Imaging outcomes for neuroprotection and repair in MS (2009)
- Disability outcomes in MS (2012)
- Defining the clinical course of MS: 2013 revisions (2014)
- Vision and Vision-Related Outcome Measures in Multiple Sclerosis (2014)
- Comorbidity in MS and its impact on clinical studies (2014-2015): a set of comprehensive systematic reviews of impact and prevalence of comorbidities in MS and recommendations for incorporating comorbidity analyses in clinical trials and observational studies
- Cell-Based Therapeutic Strategies for Multiple Sclerosis (2015)
In 2016-2017, the Committee will explore new diagnostic criteria for MS and spinal cord manifestations in MS.
